Catalyst Pharmaceuticals Q3 revenue beats estimates on FRIDAPSE growth

Catalyst Pharmaceuticals

05/11/2025 21:32

Overview

Catalyst Q3 2025 revenue grows 17.4%, beating analyst expectations

Company raises full-year 2025 revenue guidance to $565-$585 mln

Announces $200 mln share repurchase program, signaling confidence in outlook

Outlook

Catalyst raises full-year 2025 revenue guidance to $565 mln - $585 mln

Company increases 2025 AGAMREE revenue guidance to $105 mln - $115 mln

Catalyst maintains full-year 2025 FIRDAPSE revenue guidance at $355 mln - $360 mln

Result Drivers

FIRDAPSE GROWTH - Sustained organic growth and market penetration drove record FIRDAPSE revenue in Q3

AGAMREE UPTAKE - Strong demand and penetration into DMD centers contributed to AGAMREE revenue growth

FYCOMPA COMPETITION - Revenue decline due to entry of generic tablet version impacting sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$148.40 mln
$136.80 mln (7 Analysts)
Q3 Adjusted Net Income
$86.10 mln
Q3 Net Income
$52.80 mln
Q3 Operating Income
$66.30 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Catalyst Pharmaceuticals Inc is $33.00, about 35.3% above its November 4 closing price of $21.34

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nGNX4JnzTv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)